Targeted Therapies for Brain Tumors: Will They Ever Deliver?
The strategy of using biologically targeted therapeutics for cancer has yet to translate into effective treatment of gliomas. The neuro-oncology community is beginning to recognize that phase 0 studies should be performed to account for the impact of the blood-brain barrier on the ability of a therapeutic to reach its target(s). Clin Cancer Res; 24(16); 3790-1. ©2018 AACRSee related article by Sanai et al., p. 3820.